Irina Bilous | BiopharmaTrend

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <title>Irina Bilous | BiopharmaTrend</title> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <link rel="canonical" href="https://www.biopharmatrend.com/contributor/80/" />  <script async src="https://www.googletagmanager.com/gtag/js?id=G-YK7FCK71TD"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-YK7FCK71TD'); </script> <meta name="keywords" content="BiopharmaTrend team, Irina Bilous, author profile" /> <meta name="description" content="Iryna Bilous, M.S., is a biotechnologist and neuroscientist. She has experience in developing cutting the …" />  <meta name="twitter:card" content="summary"> <meta name="twitter:title" content="Irina Bilous | BiopharmaTrend"> <meta name="twitter:description" content="Iryna Bilous, M.S., is a biotechnologist and neuroscientist. She has experience in developing cutting the …"> <meta name="twitter:image" content="https://www.biopharmatrend.com/files/user/46_about_team_iryna.webp">  <meta property="og:type" content="article" /> <meta property="og:url" content="https://www.biopharmatrend.com/contributor/80/" /> <meta property="og:title" content="Irina Bilous | BiopharmaTrend" /> <meta property="og:description" content="Iryna Bilous, M.S., is a biotechnologist and neuroscientist. She has experience in developing cutting the …" /> <meta property="og:image" content="https://www.biopharmatrend.com/files/user/46_about_team_iryna.webp"> <link rel="shortcut icon" href="/static/favicon.ab1145f4d518.ico" /> <link rel="stylesheet" type="text/css" href="/static/css/main.6dead4e2266d.css" /> </head> <body> <div id="main-preheader"> <div class="container block-preheader"> <div id="logo-top"> <a href="/"><b>BioPharmaTrend</b></a>  </div> <div class="burger-container"> <div class="burger-button-container"> <button type="button" class="burger-button" onclick="document.documentElement.classList.toggle('blockfix');this.parentElement.parentElement.classList.toggle('active');"> <div class="burger-line burger-line-1"></div> <div class="burger-line burger-line-2"></div> <div class="burger-line burger-line-3"></div> </button> </div>  <div id="main-search-menu"> <div class="top-search"> <form action="/search/" class="top-search-form"> <button type="submit" class="btn btn-default"><i class="glyphicon glyphicon-search"></i></button> <input type="text" name="q" value="" size="10" class="form-control form-control-inline" required="" placeholder="e.g. 'quantum tech' or 'stem cell'"> <input type="hidden" name="section" value="insights"> </form> <span class="top-search-switcher button" onclick="this.parentElement.classList.toggle('active')"> <span class="glyphicon glyphicon-search"></span> <span class="glyphicon glyphicon-remove"></span> </span> </div> <span class="top-search-switcher button"> <span class="glyphicon glyphicon-search"></span> </span> </div>  <nav id="main-menu"> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/news/"><b>Latest News</b></a> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">All Topics <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/topic/bioeconomy-society/">Bioeconomy & Society</a></li> <li><a class="top-menu-link" href="/topic/ai-digital/">AI & Digital</a></li> <li><a class="top-menu-link" href="/topic/startups/">Startups & Deals</a></li> <li><a class="top-menu-link" href="/topic/neurotech/">NeuroTech</a></li> <li><a class="top-menu-link" href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a class="top-menu-link" href="/topic/synbio/">Biotech</a></li> <li><a class="top-menu-link" href="/topic/tools-methods/">Tools & Methods</a></li> <li><a class="top-menu-link" href="/topic/healthtech/">HealthTech</a></li> <li><a class="top-menu-link" href="/topic/aging-research/">Aging & Longevity</a></li> <li><a class="top-menu-link" href="/topic/contract-research/">Contract Research</a></li> <div class="sub-menu-margin"></div>  <li><a class="top-menu-link" href="/section/latest/">Latest insights</a></li> <li><a class="top-menu-link" href="/premium-content/">Premium Content</a></li> <div class="sub-menu-margin" style="border-bottom: 1px solid limegreen;"></div> <li><a class="top-menu-link" href="/knowledge-center/">Knowledge Center</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/interviews/"><b>Interviews</b></a> </div>  <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">Companies <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu">  <li><a class="top-menu-link" href="/m/marketplace/">Company Directory</a></li> <li><a class="top-menu-link" href="/section/interviews/">Interviews with Thought Leaders</a></li> <li><a class="top-menu-link" href="/section/case-studies/">Sponsored Case Studies</a></li> <li><a class="top-menu-link" href="/m/editor-tool/">Create Company Profile</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">More <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/about/">About Us</a></li> <li><a class="top-menu-link" href="/about/team/">Our Team</a></li> <li><a class="top-menu-link" href="/about/advisory-board/">Advisory Board</a></li> <li><a class="top-menu-link" href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a class="top-menu-link" href="/events/">Partner Events Calendar</a></li> <li><a class="top-menu-link" href="/advertising-media-kit/">Advertise with Us</a></li> <li><a class="top-menu-link" href="/contributor/">Write for Us</a></li> </ul> </div> </div> </nav> </div> <div id="main-user-actions">  <div class="mobile-menu-item"> <a href="/membership/" class="button-subscribe top-menu-link">Subscribe</a> </div>  <div class="mobile-menu-item last"> <a href="#" class="mobile-menu-item-title" rel="nofollow" title="Login/Join" onclick="document.getElementById('login-popup').classList.toggle('hidden')"> <span class="glyphicon glyphicon-log-in"></span> <span class="mobile-hide-m">Login/Join</span> </a> </div> </div> </div> </div> <div id="main-preheader-margin"></div> <div id="sencondary-menu-block"> <div class="container clearfix"> <nav> <ul class="text-center"> <li><a href="/topic/ai-digital/">AI & Digital</a></li> <li><a href="/topic/startups/">Startups & Deals</a></li> <li><a href="/topic/neurotech/">NeuroTech</a></li> <li><a href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a href="/topic/synbio/">Biotech</a></li> <li><a href="/topic/tools-methods/">Tools & Methods</a></li> </ul> </nav> </div> </div>  <div id="main-content" class="container"> <main id="content" class="col-lg-9 col-md-8 col-sm-12 col-xs-12"> <article> <div class="row"> <div class="col-lg-2 col-md-3 col-sm-4 col-xs-12"> <img src="/files/user/46_about_team_iryna.webp" class="img-circle" /> </div> <div class="col-lg-10 col-md-9 col-sm-8 col-xs-12"> <h1>Irina Bilous</h1> <div class="soc-buttons-grey"> <em>Associate Writer, Neuroscience, Clinical Trials</em>     <a href="https://www.linkedin.com/in/irina-bilous-3bb5b41a5/" target="_blank" rel="nofollow"> <img src="/static/img/sm-in.fb9ea368635d.png" width="35" height="35" /></a>   </div> </div> </div> <br> <section class="clearfix"> <p>Iryna Bilous, M.S., is a biotechnologist and neuroscientist. She has experience in developing cutting the edge neuroscience techonology - novel brain implants, along with this she was involved in brain activity and behavior research. Iryna's current primary focus is on immunooncology, as she is a part of a clinical operations team in a growing biotech start-up.</p> </section> <p style="line-height: 2.5;"> <strong>Author in </strong><br> <a href="/topic/ai-digital/posts/" class="btn btn-default">AI & Digital</a>   <a href="/topic/startups/posts/" class="btn btn-default">Startups & Deals</a>   <a href="/topic/neurotech/posts/" class="btn btn-default">NeuroTech</a>   <a href="/topic/clinical-trials/posts/" class="btn btn-default">Clinical Trials</a>   <a href="/topic/synbio/posts/" class="btn btn-default">Biotech</a>   <a href="/topic/tools-methods/posts/" class="btn btn-default">Tools & Methods</a>   <a href="/topic/aging-research/posts/" class="btn btn-default">Aging & Longevity</a>   <a href="/topic/novel-therapeutics/posts/" class="btn btn-default">Novel Therapeutics</a>   </p> </article> <hr> <section> <h3>Recent articles from Irina</h3> <article> <header> <h4><a href="/post/698-how-artificial-intelligence-is-reshaping-the-landscape-of-personalized-cancer-treatment/">Six AI-driven Drug Discovery Companies Enabling Precision Oncology</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>June 29, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 9857<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-698.jpg" alt="Six AI-driven Drug Discovery Companies Enabling Precision Oncology" /></div> <div class="post-abstract"> <p>Artificial Intelligence (AI) is steadily making its presence felt across various sectors, including the pharmaceutical industry. Among the multiple applications of AI in this field, immunotherapy - a treatment method that utilizes the body's immune system to combat diseases, notably cancer - is seeing a significant influence. The integration of AI can potentially enhance treatments and patient care by making it more precise and personalized.</p> <p> </p> <quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal> </div> </article> <article> <header> <h4><a href="/post/771-lucrative-opportunities-in-half-a-trillion-neuroscience-market-trends-and-top-companies-to-follow/">Notable Trends and Companies to Follow in Neuroscience</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>March 18, 2024</time>    <span class="glyphicon glyphicon-eye-open"></span> 2052<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-771.jpg" alt="Notable Trends and Companies to Follow in Neuroscience" /></div> <div class="post-abstract"> <p>Historically, the approval rate for medicines treating central nervous system (CNS) disorders was low. By 2022, the success rate for CNS assets from phase 1 through to regulatory submission <a href="https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/two-steps-forward-one-step-back-the-long-road-to-success-in-cns.pdf">was</a> only 5–6%.</p> <p>The failure of pharmaceutical companies to bring CNS medications to the market can be attributed to factors such as a limited understanding of disease mechanisms and challenges in delivering drugs across the blood-brain barrier. Nevertheless, recent technological advancements and an improved understanding of disease pathophysiology led to expanding the CNS pipeline.</p> <p>A <a href="https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/two-steps-forward-one-step-back-the-long-road-to-success-in-cns.pdf">recent report</a> shows that the CNS pipeline has grown by 31%, constituting 14% of the overall industry R&D pipeline. Moreover, the approval of the first drug for spinal muscular atrophy (SMA) developed by Ionis Pharma and Biogen was a significant stride that revitalized interest in the field and demonstrated the ability of innovative treatments to address complex neurological disorders.</p> </div> </article> <article> <header> <h4><a href="/post/243-7-notable-ai-companies-in-clinical-research-to-watch-in-2020/">9 Notable AI Companies in Clinical Research to Watch in 2023</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>Jan. 5, 2024</time>    <span class="glyphicon glyphicon-eye-open"></span> 20222<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-243.jpg" alt="9 Notable AI Companies in Clinical Research to Watch in 2023" /></div> <div class="post-abstract"> <p>The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about<a href="https://projectalpha.mit.edu/pos/" rel="nofollow" target="_blank"> 11%</a> for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials might fail due to the <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092479/" rel="nofollow" target="_blank">lack of financing, insufficient enrollment, or poor study design</a>.</p> <p>Artificial Intelligence (AI) is <a href="https://www.clinicalleader.com/doc/the-expanding-role-of-artificial-intelligence-in-clinical-research-0001" rel="nofollow" target="_blank">increasingly perceived as a source of opportunities</a> to improve the operational efficiency of clinical trials and minimize clinical development costs.  Typically AI vendors offer their services and expertise in the three main areas. AI start-ups in the first area help to unlock information from disparate data sources, such as scientific papers, medical records, disease registries, and even medical claims by applying Natural Language Processing (NLP). This can support patient recruitment and stratification, site selection, and improve clinical study design and understanding of disease mechanisms. As an example, about 18 % of clinical studies fail due to insufficient recruitment, as <a href="https://www.upi.com/Health_News/2015/12/30/One-in-four-cancer-trials-fails-to-enroll-enough-participants/2611451485504/" rel="nofollow" target="_blank">a 2015 study</a> reported.</p> </div> </article> <article> <header> <h4><a href="/post/696-how-ai-driven-multi-omics-for-drug-discovery-is-reshaping-medicine/">How AI-Driven Multi-Omics is Reshaping Drug Discovery</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>June 21, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 3379<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-696.jpg" alt="How AI-Driven Multi-Omics is Reshaping Drug Discovery" /></div> <div class="post-abstract"> <p>The fusion of artificial intelligence (AI) with multi-omics - a comprehensive study encompassing genomics, transcriptomics, proteomics, metabolomics, and other related fields - is heralding an era of speedier, more efficient drug discovery. AI has been disrupting various sectors, but its potential in revolutionizing the drug discovery process - traditionally a complex, time-consuming, and expensive undertaking - is garnering significant attention. The integration of AI with multi-omics approaches is enhancing the predictive power of drug discovery algorithms, minimizing risks, and expediting the journey from the bench to the bedside.</p> <quillbot-extension-portal></quillbot-extension-portal> </div> </article> <article> <header> <h4><a href="/post/697-vrg50635-a-drug-discovered-through-verge-genomics-ai-powered-planform-shows-promising-phase-1-results-for-als-treatment/">VRG50635, a Drug Discovered Through Verge Genomics' AI-powered planform, Shows Promising Phase 1 Results for ALS Treatment</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>June 20, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 2398<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-697.jpg" alt="VRG50635, a Drug Discovered Through Verge Genomics' AI-powered planform, Shows Promising Phase 1 Results for ALS Treatment" /></div> <div class="post-abstract"> <p>Verge Genomics, a frontrunner in the implementation of AI in drug discovery, recently <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-positive-safety-and-tolerability-data-from-the-phase-1-clinical-trial-of-vrg50635-a-potential-best-in-class-therapeutic-for-all-forms-of-als" rel="nofollow" target="_blank">concluded</a> the Phase 1 clinical trial of VRG50635, an investigational drug for Amyotrophic Lateral Sclerosis (ALS). The drug, developed through artificial intelligence-driven methods, was well tolerated and demonstrated safety in healthy adult volunteers. The clinical results position VRG50635 as a potential best-in-class therapeutic for all forms of ALS.</p> <p> </p> <quillbot-extension-portal></quillbot-extension-portal> </div> </article> <article> <header> <h4><a href="/post/692-iggenix-advances-therapeutic-approach-to-peanut-allergies-with-igg4-monoclonal-antibodies/">IgGenix Advances Therapeutic Approach to Peanut Allergies with IgG4 Monoclonal Antibodies</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>June 16, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 1320<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-692.jpg" alt="IgGenix Advances Therapeutic Approach to Peanut Allergies with IgG4 Monoclonal Antibodies" /></div> <div class="post-abstract"> <p>IgGenix, Inc., a California-based preclinical antibody discovery and development company, recently reported advances towards a potential therapeutic solution for peanut allergies based on IgG4 monoclonal antibodies.</p> <quillbot-extension-portal></quillbot-extension-portal> </div> </article> <article> <header> <h4><a href="/post/687-harnessing-ai-for-drug-discovery-certara-amplifies-codex-platform-capabilities/">Harnessing AI for Drug Discovery Certara Amplifies CODEX Platform Capabilities</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>June 11, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 1648<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-687.jpg" alt="Harnessing AI for Drug Discovery Certara Amplifies CODEX Platform Capabilities" /></div> <div class="post-abstract"> <p>Certara, a leader in biosimulation, has recently expanded the horizons of AI in drug discovery with<a href="https://www.certara.com/announcement/certara-enhances-codex-clinical-outcome-analytics-platform-with-ai/?utm_medium=organic_social&utm_source=linkedin.com&utm_campaign=codex-june-2023-announcement%27" rel="nofollow" target="_blank"> the introduction of artificial intelligence</a> (AI) capabilities and data fabric connectivity to its clinical trials outcome analytics platform, CODEX.</p> </div> </article> <article> <header> <h4><a href="/post/680-seqera-labs-joins-forces-with-genomics-england-to-boost-genomic-medicine-research/">Seqera Labs Joins Forces with Genomics England to Boost Genomic Medicine Research</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>June 2, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 1496<br /> </footer> <div class="post-image"><img src="/files/blog/post-cover-680.jpg" alt="Seqera Labs Joins Forces with Genomics England to Boost Genomic Medicine Research" /></div> <div class="post-abstract"> <p>Seqera Labs, recognized for its secure workflow orchestration software in the life sciences domain, <a href="https://www.pharmiweb.com/press-release/2023-05-25/seqera-labs-partners-with-genomics-england-to-enhance-genomic-research-capabilities#:~:text=The%20new%20collaboration%20between%20Seqera,disease%20and%20develop%20new%20treatments." rel="nofollow" target="_blank">is aligning forces</a> with Genomics England, a government-owned entity, which initiated the notable 100,000 Genomes Project in alliance with the NHS. This collaboration aims to enhance the scope and proficiency of whole genome analysis, paving the way for a broader patient base to avail genomic healthcare benefits.</p> <quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal> </div> </article> <article> <header> <h4><a href="/post/676-valo-therapeutics-innovative-immuno-oncology-therapy-pepticrad-1-begins-human-trials/">Valo Therapeutics' Innovative Immuno-Oncology Therapy PeptiCRAd-1 Begins Human Trials</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>May 23, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 1549<br /> </footer> <div class="post-image"><img src="/files/blog/post-2023-05-22_XsNm1Yf.jpg" alt="Valo Therapeutics' Innovative Immuno-Oncology Therapy PeptiCRAd-1 Begins Human Trials" /></div> <div class="post-abstract"> <p>Valo Therapeutics Oy (ValoTx), a frontrunner in the development of advanced immunotherapies for cancer, has initiated its Phase I trial of PeptiCRAd-1, a pioneer in the realm of immuno-oncology. The first participant, enrolled in this Germany-based trial, has received the treatment without any immediate safety issues, according to the company's recent press release.</p> <quillbot-extension-portal></quillbot-extension-portal> </div> </article> <article> <header> <h4><a href="/post/675-mitsubishi-vc-arm-leads-75m-financing-for-pharmenables-ai-in-drug-discovery-efforts/">Mitsubishi VC Arm Leads $7.5M Financing for PharmEnable's AI in Drug Discovery Efforts</a></h4> </header> <footer class="post-meta"> <span class="glyphicon glyphicon-calendar"></span> <time>May 22, 2023</time>    <span class="glyphicon glyphicon-eye-open"></span> 2360<br /> </footer> <div class="post-image"><img src="/files/blog/post-2023-05-22.jpg" alt="Mitsubishi VC Arm Leads $7.5M Financing for PharmEnable's AI in Drug Discovery Efforts" /></div> <div class="post-abstract"> <p>PharmEnable, an innovative drug discovery firm, recently <a href="https://www.globenewswire.com/news-release/2023/05/22/2673062/0/en/PharmEnable-Closes-7-5M-Financing-led-by-MP-Healthcare-to-Develop-Next-Generation-of-Small-Molecule-Drugs-to-Treat-Cancer-and-Neurological-Diseases.html" rel="nofollow" target="_blank">secured $7.5M in Pre-Series A</a> financing, reflecting growing confidence in its proprietary AI-based drug discovery platform and potential contributions to the treatment of cancer and neurological diseases. This move signifies the latest milestone in the integration of AI technology into drug discovery, a trend that's been steadily reshaping the biopharma landscape.</p> <quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal> </div> </article> </section> </main> <aside id="main-sidebar" class="col-lg-3 col-md-4 col-sm-12 col-xs-12"> </aside> </div> <footer id="main-footer"><div class="container"> <div class="row"> <div class="col-12 col-sm-6 col-lg-3"> <h4 class="footer-logo"><span style="font-weight: 900">BiopharmaTrend</span>.com</h4> <div style="margin-bottom: 1.25em" class="footer-logo-slogan">Where Tech Meets Bio</div>  <div style="margin-bottom: 0.5em;"><a href="#main-footer" onclick="toggleMailingPopup(true)" style="color: lemonchiffon"> <img src="/static/img/sm-mail.a3210e82fe37.png" alt="mail" width="32" height="32" />  <b>Newsletter</b> </a></div> <div style="margin-bottom: 0.5em"><a href="https://www.linkedin.com/company/biopharmatrend-com/" rel="nofollow" target="_blank"> <img src="/static/img/sm-in.fb9ea368635d.png" alt="in" width="32" height="32" />  LinkedIn </a></div> <div style="margin-bottom: 0.5em"><a href="https://twitter.com/BiopharmaTrend" rel="nofollow" target="_blank"> <img src="/static/img/sm-x.9f3327271e1a.png" alt="x" width="32" height="32" />  X </a></div> <div style="margin-bottom: 0.5em"><a href="https://news.google.com/publications/CAAqBwgKMOaRugsw86zRAw?hl=en-US&gl=US&ceid=US:en" rel="nofollow" target="_blank"> <img src="/static/img/sm-gnews.ac9eb4674c84.png" alt="gnews" width="32" height="32" />  Google News </a></div> <div><a href="/rss/" rel="nofollow" target="_blank"> <img src="/static/img/sm-rss.bcd2cefd2eba.png" alt="rss" width="32" height="32" />  RSS Feed </a></div> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>About</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/about/">What we do</a></li> <li><a href="/editorial-calendar/">Editorial Calendar</a></li> <li><a href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a href="/terms-of-use/">Terms of Use</a></li> <li><a href="/privacy-policy/">Privacy Policy</a></li>  <li><a href="/about/disclaimer/">Disclaimer</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>We Offer</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/premium-content/"><b style="color: lemonchiffon">Premium Content</b></a></li> <li><a href="/m/marketplace/">BioTech Scout</a></li> <li><a href="/our-products/">Reports</a></li> <li><a href="/section/interviews/">Interviews</a></li> <li><a href="/events/">Partner Events</a></li> <li><a href="/section/case-studies/">Case Studies</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>Opportunities</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/membership/">Membership</a></li> <li><a href="/advertising-media-kit/">Advertise</a></li> <li><a href="/m/editor-tool/">Submit Company</a></li> <li><a href="/contributor/">Write for Us</a></li> <li><a href="/guest-blog/guidelines/">Author Guidelines</a></li> <li><a href="/a/contact/">Contact Us</a></li> </ul> </nav> </div> </div> <hr> <div class="text-right">© BPT Analytics LTD 2024</div> </div></footer> <div id="bpt-consent"><div class="container"> <div class="row"> <div class="col-12 col-md-6 col-lg-8"> We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our <a href="/cookies-policy/">cookies policy</a>. </div> <div class="col-12 col-md-6 col-lg-4 text-right"> <button class="btn btn-primary btn-sm" type="button" onclick="changeConsent('analytics')" style="white-space:unset">Agree</button> </div> </div> </div></div> <div id="login-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div class="popup-content" style="width: 25em;"> <form method="post" class="api-form" action="/a/login/?next=/contributor/80/"></form> </div> </div> <div id="subscription-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div id="subscription-popup-iframe" class="popup-content" style="width: 25em;"> </div> </div> <div id="scroll-top-pixel-anchor"></div> <button id="go-top" onclick="window.scrollTo({top: 20, left: 0, behavior: 'smooth'})">^</button> <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script> <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/js/bootstrap.min.js"></script> <script src="/static/js/main.df923d2272d3.js"></script> <script type="text/javascript"> if ( "IntersectionObserver" in window && "IntersectionObserverEntry" in window && "intersectionRatio" in window.IntersectionObserverEntry.prototype ) { let observer = new IntersectionObserver(entries => { if (entries[0].boundingClientRect.y < 0) { document.body.classList.add("scroll-top"); } else { document.body.classList.remove("scroll-top"); } }); observer.observe(document.getElementById("scroll-top-pixel-anchor")); } </script> </body> </html>

CINXE.COM

Irina Bilous | BiopharmaTrend